First, as known from KEYNOTE-024 [63], in patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer PFS and OS and a higher response rate. Here, CD274 is linked to neoplasm.